{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:31:42Z","timestamp":1787002302242,"version":"build-2736575974"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/ki.2014.354","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T10:23:40Z","timestamp":1419935020000},"page":"17-19","source":"Crossref","is-referenced-by-count":19,"title":["New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy"],"prefix":"10.1016","volume":"87","author":[{"given":"Peter F.","family":"Hoyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2014.354_bb0010","first-page":"CD001533","article-title":"Corticosteroid therapy for nephrotic syndrome in children","volume":"4","author":"Hodson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1038\/ki.2014.354_bb0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","article-title":"Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO","volume":"28","author":"Lombel","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2014.354_bb0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.2014.240","article-title":"Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome","volume":"87","author":"Sinha","year":"2015","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.354_bb0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ki.2014.260","article-title":"A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment","volume":"87","author":"Yoshikawa","year":"2015","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.354_bb0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.2005090922","article-title":"Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial","volume":"17","author":"Hoyer","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2014.354_bb0035","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00467-003-1170-9","article-title":"Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook","volume":"18","author":"Vester","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2014.354_bb0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF01956754","article-title":"Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie","volume":"152","author":"Ehrich","year":"1993","journal-title":"Eur J Pediatr"},{"key":"10.1038\/ki.2014.354_bb0045","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","article-title":"Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome","volume":"24","author":"Gellermann","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2014.354_bb0050","doi-asserted-by":"crossref","first-page":"e55980","DOI":"10.1371\/journal.pone.0055980","article-title":"Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling","volume":"8","author":"Jeruschke","year":"2013","journal-title":"PLoS One"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815300375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815300375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T09:20:55Z","timestamp":1598606455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815300375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0085253815300375"],"URL":"https:\/\/doi.org\/10.1038\/ki.2014.354","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}